• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Outset Medical Inc. (Amendment)

    4/10/24 11:09:13 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $OM alert in real time by email
    SC 13G/A 1 d824955dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Amendment #1

    Under the Securities and Exchange Act of 1934

     

     

    Outset Medical, Inc

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    690145107

    (CUSIP Number)

    March 31, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    This Schedule is filed pursuant to Rule 13d-1(b)

    The information required in the remainder of this cover page (except any items to which the form provides a cross-reference) shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP NO. 690145107

     

     1)   

     Name of Reporting Person

     Ameriprise Financial, Inc.

     

     S.S. or I.R.S. Identification No. of Above Person

     IRS No. 13-3180631

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)    

     Sole Voting Power

     

     0

       6)   

     Shared Voting Power

     

     5,112,402

       7)   

     Sole Dispositive Power

     

     0

       8)   

     Shared Dispositive Power

     

     5,112,408

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,112,408

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     10.12%

    12)  

     Type of Reporting Person

     

     HC


    CUSIP NO. 690145107

     

     1)   

     Name of Reporting Person

     Columbia Management Investment Advisers, LLC

     

     S.S. or I.R.S. Identification No. of Above Person

     IRS No. 41-1533211

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     Minnesota

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)    

     Sole Voting Power

     

     0

       6)   

     Shared Voting Power

     

     3,801,738

       7)   

     Sole Dispositive Power

     

     0

       8)   

     Shared Dispositive Power

     

     3,801,738

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,801,738

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     7.53%

    12)  

     Type of Reporting Person

     

     IA


    CUSIP NO. 690145107

     

     1)   

     Name of Reporting Person

     Columbia Wanger Asset Management, LLC

     

     S.S. or I.R.S. Identification No. of Above Person

     IRS No. 04-3519872

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)    

     Sole Voting Power

     

     0

       6)   

     Shared Voting Power

     

     3,599,098

       7)   

     Sole Dispositive Power

     

     0

       8)   

     Shared Dispositive Power

     

     3,599,098

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,599,098

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     7.13%

    12)  

     Type of Reporting Person

     

     IA


    CUSIP NO. 690145107

     

     1)   

     Name of Reporting Person

     Columbia Acorn Fund

     

     S.S. or I.R.S. Identification No. of Above Person

     IRS No. 36-2692100

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     Massachusetts

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)    

     Sole Voting Power

     

     3,023,976

       6)   

     Shared Voting Power

     

     0

       7)   

     Sole Dispositive Power

     

     0

       8)   

     Shared Dispositive Power

     

     3,023,976

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,023,976

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     5.99%

    12)  

     Type of Reporting Person

     

     IV


    1(a)    Name of Issuer:    Outset Medical, Inc
    1(b)    Address of Issuer’s Principal    3052 Orchard Drive
       Executive Offices:    San Jose, California 95134
    2(a)    Name of Person Filing:    (a) Ameriprise Financial, Inc. (“AFI”)
          (b) Columbia Management Investment Advisers, LLC (“CMIA”)
          (c) Columbia Wanger Asset Management, LLC (“CWAM”)
          (d) Columbia Acorn Fund (“Fund”)
    2(b)    Address of Principal Business Office:    (a) Ameriprise Financial, Inc.
          145 Ameriprise Financial Center
          Minneapolis, MN 55474
          (b) 290 Congress St.
          Boston, MA 02210
          (c) 71 S Wacker Drive, Suite 2500
          Chicago, IL 60606
          (d) 71 S Wacker Drive, Suite 2500
          Chicago, IL 60606
    2(c)    Citizenship:    (a) Delaware
          (b) Minnesota
          (c) Delaware
          (d) Massachusetts
    2(d)    Title of Class of Securities:    Common Stock
    2(e)    Cusip Number:    690145107

     

    3

    Information if statement is filed pursuant to Rules 13d-1(b) or 13d-2(b):

    (a) Ameriprise Financial, Inc.

    A parent holding company in accordance with Rule 13d-1(b)(1)(ii)(G). (Note: See Item 7)

    (b) Columbia Management Investment Advisers, LLC

    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

    (c) Columbia Wanger Asset Management, LLC

    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

    (d) Columbia Acorn Fund

    An investment company registered under Section 8 of the Investment Company Act.


    4

    Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person.

    CMIA, CWAM and AFI do not directly own any shares of Common Stock of the issuer. As the investment adviser to the Fund and various other unregistered and registered investment companies and other managed accounts, CMIA and CWAM may be deemed to beneficially own the shares reported herein by the Fund. Accordingly, the shares reported herein by CMIA and CWAM include those shares separately reported herein by the Fund.

    AFI, as the parent company of CMIA and CWAM, may be deemed to beneficially own the shares reported herein by those reporting persons. Accordingly, the shares reported herein by AFI include those shares separately reported herein by those reporting persons.

    Each of AFI, CMIA and CWAM disclaims beneficial ownership of any shares reported on this Schedule.

     

    5

    Ownership of 5% or Less of a Class: Not Applicable

     

    6

    Ownership of more than 5% on Behalf of Another Person:

    To the knowledge of AFI, CMIA, CWAM and the Fund, no other persons besides AFI, CMIA, CWAM and the Fund and those persons for whose shares of common stock CMIA, CWAM and AFI report beneficial ownership have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities of the issuer reported herein. As of March 31, 2024, only the Fund owned more than 5% of the class of securities reported herein.

    Any remaining shares reported herein by CMIA and CWAM are held by various other funds or accounts managed by CMIA and CWAM which each have the right to receive any dividends paid by the issuer and could terminate their respective investment advisory relationship with CMIA and CWAM and then subsequently direct the use of proceeds from the sale of the common stock owned by such fund or account. To CMIA’s and CWAM’s knowledge, none of these other funds or accounts own more than 5% of the outstanding shares of the issuer as March 31, 2024.

     

    7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

    AFI: See Exhibit I

     

    8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    9

    Notice of Dissolution of Group:

    Not Applicable


    10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

    Dated: April 10, 2024

     

    Ameriprise Financial, Inc.
    By:   /s/ Michael G. Clarke
    Name:   Michael G. Clarke
    Title:   Senior Vice President, North America Head of Operations & Investor Services

     

    Columbia Management Investment Advisers, LLC
    By:   /s/ Michael G. Clarke
    Name:   Michael G. Clarke
    Title:   Senior Vice President, North America Head of Operations & Investor Services

     

    Columbia Wanger Asset Management, LLC
    By:   /s/ Michael G. Clarke
    Name:   Michael G. Clarke
    Title:   Chief Financial Officer and Assistant Treasurer

     

    Columbia Acorn Fund
    By:   /s/ Michael G. Clarke
    Name:   Michael G. Clarke
    Title:   Treasurer

     

    Contact Information

    Dominic Geddes

    Global Head of Reporting

    Global Operations and Investor Services

    Telephone: +442074645779


    Exhibit Index

     

    Exhibit I    Identification and Classification of the Subsidiary which acquired the Security Being Reported on by the Parent Holding Company.
    Exhibit II    Joint Filing Agreement

     

    Get the next $OM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OM

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    6/21/2024$5.00 → $6.00Sector Perform → Outperform
    RBC Capital Mkts
    4/8/2024$6.00Buy
    BTIG Research
    4/5/2024$6.00Neutral → Buy
    CL King
    1/12/2024$14.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    10/13/2023$32.00 → $3.00Buy → Underperform
    BofA Securities
    8/17/2023Neutral
    CL King
    11/11/2022$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $OM
    SEC Filings

    View All

    SEC Form 144 filed by Outset Medical Inc.

    144 - Outset Medical, Inc. (0001484612) (Subject)

    8/15/25 7:57:18 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Outset Medical, Inc. (0001484612) (Filer)

    8/6/25 4:15:10 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SCHEDULE 13G filed by Outset Medical Inc.

    SCHEDULE 13G - Outset Medical, Inc. (0001484612) (Subject)

    7/29/25 2:14:28 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chair and CEO Trigg Leslie sold $11,644 worth of shares (904 units at $12.88), decreasing direct ownership by 0.73% to 122,328 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:05:30 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SVP Operations and R&D Nash Marc sold $3,130 worth of shares (243 units at $12.88), decreasing direct ownership by 0.56% to 42,898 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:01:44 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    General Counsel Brottem John L. sold $4,933 worth of shares (383 units at $12.88), decreasing direct ownership by 0.81% to 46,883 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:00:16 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously

    8/8/24 6:47:35 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously

    6/21/24 6:53:06 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on Outset Medical with a new price target

    BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00

    4/8/24 7:26:20 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference

    SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the 23rd annual Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 7 a.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc. Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind techno

    8/20/25 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Names First Chief Nursing Officer

    SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced Brittni McGill has been named to the newly created role of Chief Nursing Officer where she will apply her extensive nurse executive leadership experience to help increase strategic outreach and clinical program innovation designed to empower nurses and nurse leaders and elevate care. "Our entire Outset team understands and celebrates the critical role the nursing community and specifically, nurse executives, play in ensuring successful patient outcomes across

    7/30/25 9:01:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Financials

    Live finance-specific insights

    View All

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on W

    7/16/25 4:03:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

    SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma

    5/7/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

    SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

    5/14/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Outset Medical Names Business Leader Dale E. Jones to Board of Directors

    Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking

    4/25/22 4:00:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:53:46 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:26:01 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 10:32:13 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care